2654003-64-0

2654003-64-0 structure
2654003-64-0 structure
  • Name: CDK7-IN-8
  • Chemical Name: CDK7-IN-8
  • CAS Number: 2654003-64-0
  • Molecular Formula: C25H38N8O3
  • Molecular Weight: 498.62
  • Catalog: Signaling Pathways Cell Cycle/DNA Damage CDK
  • Create Date: 2022-05-21 18:39:29
  • Modify Date: 2025-08-27 12:02:31
  • CDK7-IN-8 is a potent CDK7 inhibitor with IC50 of 54.29 nM. CDK7-IN-8 has inhibitory effect on certain cancer cells and in vivo tumor models[1].

Name CDK7-IN-8
Description CDK7-IN-8 is a potent CDK7 inhibitor with IC50 of 54.29 nM. CDK7-IN-8 has inhibitory effect on certain cancer cells and in vivo tumor models[1].
Related Catalog
Target

CDK7:54.29 nM (IC50)

In Vitro CDK7-IN-8 (0-100 nM; 72 hours) has inhibitory effect on HCC70, OVCAR-3, HCT116 and HCC1806 cells, with IC50 of 50.85 nM, 45.31 nM, 25.26 nM and 44.47 nM respectively[1]. Cell Proliferation Assay Cell Line: HCC70, OVCAR-3, HCT116 and HCC1806 cells[1] Concentration: 0-100 nM Incubation Time: 72 hours Result: Exhibited inhibitory effect on HCC70, OVCAR-3, HCT116 and HCC1806 cells, with IC50 of 50.85 nM, 45.31 nM, 25.26 nM and 44.47 nM respectively.
In Vivo CDK7-IN-8 (20 or 40 mg/kg; i.g., single) has good advantages Pharmacokinetic properties[1]. CDK7-IN-8 (25 mg/kg; p.o., qd, for 21 days) effectively inhibits tumor proliferation with tumor growth inhibition (TGI) value of 81.9%[1]. Pharmacokinetic Parameters of CDK7-IN-8 in male ICR mice[1]. IG (20 mg/kg) IG (40 mg/kg) T1/2 (h) 1.48 2.99 Tmax (h) 0.50 4.67 Cmax (ng/mL) 3379.92 783.01 AUC0-t (h*ng/mL) 6258.34 7828.87 AUC0-∞ (h*ng/mL) 6375.00 7879.45 Animal Model: Male ICR mice [1] Dosage: 20 or 40 mg/kg Administration: i.g., single (pharmacokinetic analysis) Result: Showed good advantages Pharmacokinetic properties. Animal Model: Male BALB/c nude mice (injected with HCT116 tumor cells)[1] Dosage: 25 mg/kg Administration: p.o., qd, for 21 days Result: Effectively inhibited tumor proliferation with tumor growth inhibition (TGI) value of 81.9%.
References

[1]. Hu Yonghan, et al. Heterocyclic compound, and pharmaceutical composition thereof, preparation method therefor, intermediate thereof and application thereof. WO2021121390

Molecular Formula C25H38N8O3
Molecular Weight 498.62
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.